Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 175

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 169 170 171 172 173 174 < 175 > 176 177 178 179 180 181 .. 184 >> Следующая

36. White WB, Faich G, Borer JS, Makuch R. Cardiovascular thrombotic events are not increased on the cyclooxygenase-2 inhibitor —
celecoxib. ACR 66th Annual Scientific Meeting, New Orleans, 2002; 485.
37. Reicin AS, Shapiro D, Sperlong RS et al. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory druds (ibuprofen, diclofenac and nabumeton). Am Cardiol 2002; 89: 204— 209.
38. Lander SA, Wallace DJ, Weisman MH Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002; 11: 340—347.
39. Van Hecken A, Schwarts JL, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin Pharm 2000; 40: 1109—1120.
40. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction.Arch Intern Med 2002; 162; 1111—1115.
41. Solomon DH, Glynn RJ, Levone R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction Arch Intern Med 2002; 162: 1099—1104.
42. Watson DJ, Rhodes T, Cai B, Guess HA. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002; 162: 1105—1110.
43. Brochier ML. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur Heart J1993; 14: 951—957.
44. Cataldo G, Heiman F, Lavenzzari M, Ma-rubini E. Indobufen compared with aspirin and dipiridamol on graft patency after coronary bypass surgery: results of a combined analysis. Coron Arter Dis 1998; 9: 217—222.
45. Sajadieh A, Wendelboe O, Hansen JF, Mostensen LS. Non steroidal anti-inflammatory drugs after myovardial infarction. DAVIT Study Groiu, Danish Verapamil Infarction Trial. Am J Vardiol 1999; 83: 1263—1265.
46. Hudson M, Baron M, Rahme E, Pilot L. Anti-inflammatory drugs with a decrease risk of recurrent acute myocardial infarction in patients
SHS-OOO4.qxd 21.11.2006 16:56 Page
25
ГЛАВА 14. Новые подходы к профилактике и лечению антифосфолипидного синдрома
on aspirin. ACR 66th Annual Scientific Meeting, New Orleans, 2002;1663 (abst).
47. Ko D, Wang Y, Berger AK, et al. Nonsteroidal anti-inflammatory drugs after acute myocardial infarction. Am Heart J 2002; 143: 475—481.
48. Garcia Rodriguez LA. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemilog-ic data. Clin Exp. Rheumatol. 2001; 19 (suppl. 25): S41—S45.
49. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359: 118—123.
50. Bak S, Andersen M, Tsiropoulos I, et al. Risk of stroke associated with nonstweroidal anti-inflammatory drugs, Stroke 2003;3 4: 379—395.
51. Layton D, Hughes K, Harris S, Shakir SAW. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescribtion-Events Monitoring (PEM) data. Rheumatology 2003; 42: 1— 11.
52. Vane JB. Back to an aspirin a day. Science 2002; 296: 474—475.
53. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med 2001; 345: 1809—1817.
54. Van Solingen RM, Rosenstein ED, Mihai-lescu G, et al. Comparison of the effects of ketopro-fen on platelet function in the presence and absence of aspirin Am. J Med 2001; 111: 285—289.
55. Ouellett M, Riendeau D, Percival D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced intereference of platelet cyclooxygenase-1 inactivation by aspirin. PNAS 2001; 98: 14583—14588.
56. Greenberg H, Gottesdiener K, Huntington M, et al. A new cyclooxygenase-2 inhibitor, rofe-coxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharm 2000; 40: 1509—1515.
57. MacDonald TN, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573—574.
58. Kurth T, Glynn RJ, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 2003; 108: 1191—1195.
59. Derry S, Loke YK. Risk of gastrointestinal haemorrage with long term use of aspirin. BMJ 2000; 321: 1183—1187.
60. Pickard AS, Scumock GT. Aspirin use may change cost-effectiveness of COX-2 inhibitors. Arch Intern Med 2002; 162: 2637—2639.
61. Fendrick AN, Garabedian-Rufallo SM. A clinician,s guide to the selection of NSAID therapy. Pharm Ther 2002; 27: 579—582.
62. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteo-arthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis saferty. JAMA 2000; 284: 1247—1255.
Предыдущая << 1 .. 169 170 171 172 173 174 < 175 > 176 177 178 179 180 181 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed